$ALNY Phase 3 meets end point; Gets Analysts’ love

Alnylam Pharmaceuticals (ALNY) successfully completed a Phase 3 clinical trial, APOLLO, assessing RNAi therapeutic Patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy, and met its primary endpoint.

Gets Analyst love:

Analyst Action Rating Target
Cowen and Company Reiterates Outperform $93.00 -> $117.00
JMP Securities Raises Target Outperform $101.00 -> $128.00
Needham & Company LLC Raises Target $85.00 -> $125.00
Piper Jaffray Companies Reiterates Overweight $110.00 -> $116.00
Stifel Nicolaus Reiterates Hold $56.00 -> $83.00

Check out more such briefs in our Daily Pharma Scoop at SeekingAlpha Marketplace.